Preface
No senolytic agent holds any regulatory approval for ageing, longevity, or age-related functional decline; all such use is off-label and, on the current evidence base, best regarded as experimental. Human data are confined to short (<3 month) early-phase trials in specific diseases that establish feasibility and target engagement (reduced p16/p21-positive cell burden) but have not demonstrated benefit on any hard clinical outcome, and the largest randomised trial to date was negative on its primary endpoint.[1][2][3][4] The originators of the field state explicitly that “it is too early for senolytics to be used outside of clinical trials”.[4] This summary supports informed, cautious practice; it does not endorse routine clinical use.
1. Scope
Covers the first-generation small-molecule senolytics used or requested in longevity practice — principally the combination dasatinib plus quercetin (D+Q) and the flavonoid fisetin, with brief mention of navitoclax and later agents — as adjuncts to, not replacements for, conventional primary/secondary care.
Not covered in depth: senomorphics (rapamycin/rapalogs, metformin, resveratrol), which suppress the senescence-associated secretory phenotype (SASP) without killing senescent cells and are mechanistically and clinically distinct; disease-specific use of dasatinib in haemato-oncology; and preclinical-only agents (FOXO4-DRI, UBX-series, procyanidin C1, HSP90 inhibitors), which are flagged but not recommended.[5][6]
2. Background and pathophysiology
– Cellular senescence is a state of stable cell-cycle arrest with apoptosis resistance and an altered, pro-inflammatory secretome (SASP). Senescent cells accumulate with age and at sites of chronic disease.[7][4][1]
– Rationale: senescent cells are apoptosis-resistant through up-regulated anti-apoptotic (SCAP) pathways (BCL-2/BCL-xL, PI3K/AKT, tyrosine kinases). Senolytics transiently disable these defences, triggering apoptosis selectively in senescent cells. Because reaccumulation takes weeks, dosing is intermittent (“hit-and-run”) rather than continuous.[4]
– Targets: dasatinib (tyrosine kinases; senescent mesenchymal cells/preadipocytes); quercetin and fisetin (PI3K/AKT; senescent endothelial cells); navitoclax (BCL-2/BCL-xL/BCL-w).[5][8][4]
Most robust human mechanistic evidence:
– In humans, higher senescent-cell burden correlates with worse physical function (thigh adipose p16⁺ cells inversely correlated with grip strength r≈−0.74 and walking speed r≈−0.73) and higher mortality; in the Mayo biobank 14 senescence biomarkers predicted death (strongest GDF-15, HR 1.79 per SD). These are associations, not causal or interventional data.[1]
– Early-phase trials show D+Q reduces p16/p21⁺ cells and adipose senescent-cell burden in patients — i.e. target engagement is demonstrated in humans.[1][9]
Preclinical only (clearly separated; not a basis for clinical benefit claims): in mice, D+Q and fisetin reduce senescent-cell burden, improve physical function and, in naturally aged animals, increased post-treatment survival by 36%; senolytics improve cardiac ejection fraction, vascular reactivity and reduce atherosclerosis/calcification in rodent models.[10][5] Fisetin and procyanidin C1 extend mouse lifespan.[6] Animal and in-vitro findings do not translate directly to human outcomes.
The following table from the 2025 JAMA geroscience review situates senolytics among candidate ageing-biology interventions and summarises the human data:
Table 1 Select Interventions Hypothesized to Have Benefits Related to Effects on the Biology of Aging in Humans
3. Evidence base and grading
Available human evidence: several phase 1/2 RCTs and open-label pilots, typically small (n≈12–60) and short (<3 months), in idiopathic pulmonary fibrosis (IPF), diabetic kidney disease, mild cognitive impairment/early Alzheimer’s, diabetic macular oedema and post-menopausal bone turnover. No large RCTs, no meta-analyses of clinical outcomes, and no mortality/morbidity data exist.[1][2][3][4] Outcomes studied to date are predominantly surrogate/biomarker (p16/p21⁺ cell counts, SASP factors, bone-turnover markers) with limited functional endpoints.
GRADE-style certainty by outcome (all downgraded heavily for indirectness — disease-specific rather than longevity populations — and imprecision):
– Senescent-cell / SASP biomarker reduction: Low certainty that D+Q reduces senescent-cell burden (small phase 1 trials, target engagement shown but heterogeneous assays, tiny samples).[1][9]
– Physical function / frailty: Very low certainty; pilot signals only, trials underpowered for function.[3][4]
– Bone metabolism: Moderate-to-low certainty of no effect on the primary endpoint — one phase 2 RCT (n=60) found no difference in CTx at 20 weeks; secondary/exploratory signals only.[2]
– Cardiovascular, cognitive, mortality, all-cause morbidity: Very low / no human evidence; benefit unclear.[1][8]
Strength of recommendation:
– Only in research (all longevity indications): senolytics for healthy ageing, “prevention”, or biomarker optimisation. Rationale: no demonstrated clinical benefit, off-label, unknown long-term safety.[4]
– Recommend against routine clinical use outside trials or a rigorously consented adjunctive framework with registry follow-up.
4. Patient selection and indications
There is no evidence-based indication for senolytics in a longevity clinic. If considered at all, it should be within a trial or a structured off-label, fully-consented, monitored pathway.
Populations in whom research interest is greatest (hypothesis-generating, not indications):
– Older adults with measurable frailty/physical dysfunction and plausibly high senescent-cell burden.[1][4]
– Patients with an established senescence-associated disease already under specialist care (e.g. IPF, diabetic kidney disease) — but here trial enrolment is preferred.[3][9]
– Exploratory data suggest response may be greatest in those with high baseline senescent-cell burden (post-hoc, hypothesis only).[2]
Exclusion / high-risk groups (avoid or specialist input only):
– Active malignancy or recent chemotherapy; significant cytopenias (dasatinib and navitoclax cause thrombocytopenia/neutropenia).[11]
– Cardiac disease with QT prolongation, pleural/pericardial effusion history, or fluid retention (dasatinib class effects).
– Anticoagulant/antiplatelet therapy (bleeding risk with quercetin/fisetin CYP and platelet effects, dasatinib thrombocytopenia).
– Significant hepatic or renal impairment; drugs with strong CYP3A4 interaction.
– Pregnancy and breastfeeding — avoid.
Regulatory/ethical status: dasatinib is licensed only for Ph⁺ CML/ALL; quercetin and fisetin are marketed as food supplements with no medicinal licence; navitoclax is investigational. All longevity use is off-label/unlicensed. UK practice implies GMC off-label prescribing responsibilities, documented informed consent, and — ideally — enrolment in a trial or registry (MHRA/GMC framework).[4]
5. Assessment and baseline work-up
– History/examination: full medication review (CYP3A4 interactions, anticoagulants), bleeding history, cardiac history (QT, effusions), malignancy screen, frailty assessment (e.g. gait speed, grip strength, a validated frailty index).
– Baseline investigations: FBC (platelets, neutrophils), U&E/eGFR, LFTs, glucose/HbA1c, lipids; ECG (QTc) if using dasatinib; pregnancy test where relevant.
– Ageing/senescence biomarkers: no validated, clinically actionable senescence biomarker exists for individual decision-making; p16/p21, SASP panels and GDF-15 are research tools only and should not drive treatment or be presented as proof of benefit. Document them only for research/registry purposes.[1]
– Risk stratification: categorise by bleeding/cytopenia risk, cardiac risk, and interaction burden; higher risk mandates specialist input or exclusion.
6. Dosing regimens and practical implementation
No regimen is supported by robust clinical-outcome data; all below are extrapolated from early-phase trials and require caution.
Regimens used in human trials (intermittent):
– D+Q (IPF phase 1 RCT): dasatinib 100 mg/day + quercetin 1250 mg/day for 3 consecutive days per week × 3 weeks.[3]
– D+Q (bone phase 2 RCT): dasatinib 100 mg + quercetin 1000 mg on 2 consecutive days, once monthly × 5 months.[2]
– Fisetin: intermittent high-dose flavonoid regimens are under study (e.g. 20 mg/kg/day for 2 consecutive days) but no dose–response or efficacy data in ageing; trials ongoing.[6][8]
There is no established loading/maintenance or validated titration; intermittent “hit-and-run” dosing reflects senescent-cell reaccumulation kinetics, not optimised human pharmacodynamics.[4] Navitoclax is not appropriate for longevity use given dose-limiting thrombocytopenia.[11]
7. Monitoring, safety and follow-up
Monitoring:
– FBC before and after each cycle (thrombocytopenia, neutropenia).[11]
– LFTs, U&E, symptom review; ECG/QTc with dasatinib; assess for fluid retention/effusion.
– Functional measures (gait speed, grip) at baseline and follow-up for the individual patient; senescence biomarkers for research only.
– Timepoints: review after first cycle, then at each cycle; medium-term (3–6 months) functional and safety review; long-term surveillance undefined by evidence.
Adverse effects (from early trials/class knowledge):
– Common, generally mild/transient: in the D+Q IPF RCT, sleep disturbance and anxiety were disproportionately reported (4/6 vs 0/6); GI upset, fatigue, headache; no serious drug-related AEs and full regimen completion.[3]
– Dasatinib class effects: cytopenias, fluid retention/pleural effusion, QT prolongation, bleeding, GI upset.[11]
– Serious but rare: significant thrombocytopenia/neutropenia, bleeding, effusions.[11]
– Actions: hold/reduce for significant cytopenias or new effusion; stop and refer for serious AEs.
Interactions: dasatinib is CYP3A4-metabolised (avoid strong inhibitors/inducers, antacids/PPIs reduce absorption); quercetin/fisetin inhibit CYP and P-gp and may potentiate anticoagulants/antiplatelets and other substrates. Reconcile against all longevity-clinic and conventional medications.
Special populations: avoid in pregnancy/breastfeeding; caution/avoid in renal or hepatic impairment; in frailty and extremes of age the risk-benefit is unquantified and generally unfavourable outside research.
8. Contraindications and cautions
– Absolute: pregnancy/breastfeeding; active malignancy under treatment; significant baseline cytopenia or active bleeding; known hypersensitivity.
– Relative / specialist advice: anticoagulant or antiplatelet therapy; cardiac disease with QT prolongation or effusion history; hepatic/renal impairment; strong CYP3A4 interactions; significant frailty/polypharmacy.
– Harm likely to outweigh benefit: any use justified solely by biomarker “optimisation” or generic anti-ageing goals, given the absence of demonstrated clinical benefit.[4][1]
9. Practical management scenarios
Scenario A — Middle-aged adult with multiple cardiometabolic risk factors.
– Recommendation: Avoid / only in research. No evidence senolytics reduce cardiometabolic events; human CVD data absent.[1][5]
– Management: optimise guideline-based cardiometabolic care (lipids, BP, glycaemia, weight, exercise) — this is where proven mortality benefit lies. If the patient still wishes to pursue senolytics, signpost to a clinical trial; if proceeding off-label, full documented consent, baseline bloods/ECG, intermittent trial-derived D+Q dosing, FBC monitoring each cycle, and stop for any significant AE.
Scenario B — Older, frail patient with multimorbidity.
– Recommendation: Avoid outside research. Highest theoretical interest but also highest interaction/cytopenia/bleeding risk and no outcome evidence.[2][11][4]
– Management: comprehensive geriatric assessment, deprescribing, exercise and nutrition (evidence-based for frailty). Consider trial referral only. If off-label use is pursued exceptionally, involve geriatric/specialist input, minimise regimen, monitor FBC and function closely, and predefine stopping rules.
Scenario C — Adjunct in a patient already under specialist care for a senescence-associated disease (e.g. IPF, diabetic kidney disease).
– Recommendation: Restrict to research / specialist-led. Existing human trials are in exactly these populations and remain phase 1/2.[3][9]
– Management: do not initiate independently of the treating specialist; refer to or co-manage within a trial. Ensure no interaction with disease-specific therapy (e.g. antifibrotics); coordinate monitoring.
Across all scenarios, escalate/refer for cytopenia, bleeding, new effusion, cardiac symptoms or QTc change, and stop if no clear individual benefit.
10. Research gaps and future directions
– No hard-outcome data: effects on mortality, cardiovascular events, dementia, disability and healthspan are unknown; benefit of reducing senescent cells in humans “remains unclear”.[1]
– Surrogate-to-outcome linkage unproven: p16/p21 and SASP reduction have not been shown to translate to clinical benefit; must not be inferred.[1]
– Optimal agent, dose, schedule and duration are undefined; intermittent dosing is mechanistically reasoned, not clinically optimised.[4]
– Responder identification: the hypothesis that high baseline senescent-cell burden predicts response needs prospective testing.[2]
– Long-term safety of repeated intermittent senolysis in non-diseased ageing adults is unstudied.
– Priority: adequately powered, long-duration RCTs with functional and clinical endpoints; validated senescence biomarkers; standardised assays. Current practice should be confined to well-designed trials or registries.[4]
References
- Geroscience. Kritchevsky SB, Cummings SR. JAMA. 2025;334(12):1094-1102. doi:10.1001/jama.2025.11289.
- Effects of Intermittent Senolytic Therapy on Bone Metabolism in Postmenopausal Women: A Phase 2 Randomized Controlled Trial. Farr JN, Atkinson EJ, Achenbach SJ, et al. Nature Medicine. 2024;30(9):2605-2612. doi:10.1038/s41591-024-03096-2.
- Senolytics Dasatinib and Quercetin in Idiopathic Pulmonary Fibrosis: Results of a Phase I, Single-Blind, Single-Center, Randomized, Placebo-Controlled Pilot Trial on Feasibility And tolerability. Nambiar A, Kellogg D, Justice J, et al. EBioMedicine. 2023;90:104481. doi:10.1016/j.ebiom.2023.104481.
- Senolytic Drugs: From Discovery to Translation. Kirkland JL, Tchkonia T. Journal of Internal Medicine. 2020;288(5):518-536. doi:10.1111/joim.13141.
- Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
- Senescence, Aging and Disease Throughout the Gastrointestinal System. Ferreira-Gonzalez S, Matsumoto T, Hara E, Forbes SJ. Gastroenterology. 2025;169(7):1357-1379. doi:10.1053/j.gastro.2025.06.010.
- Cellular Senescence and Senolytics: The Path to the Clinic. Chaib S, Tchkonia T, Kirkland JL. Nature Medicine. 2022;28(8):1556-1568. doi:10.1038/s41591-022-01923-y.
- Cellular Senescence, Inflammaging and Cardiovascular Disease. Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Immunological Reviews. 2026;337(1):e70084. doi:10.1111/imr.70084.
- Strategies for Late Phase Preclinical and Early Clinical Trials of Senolytics. Wissler Gerdes EO, Misra A, Netto JME, Tchkonia T, Kirkland JL. Mechanisms of Ageing and Development. 2021;200:111591. doi:10.1016/j.mad.2021.111591.
- Senolytics Improve Physical Function and Increase Lifespan in Old Age. Xu M, Pirtskhalava T, Farr JN, et al. Nature Medicine. 2018;24(8):1246-1256. doi:10.1038/s41591-018-0092-9.
- SATB1, senescence and senescence‐related diseases. Qi W, Bai J, Wang R, Zeng X, Zhang L. Journal of Cellular Physiology. 2024;239(8):e31327. doi:10.1002/jcp.31327.